Nuveen Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-94,039
| Closed | -$9.59M | – | 3220 |
|
|
2023
Q2 | $9.59M | Sell |
94,039
-17,082
| -15% | -$1.74M | ﹤0.01% | 1532 |
|
|
2023
Q1 | $10.1M | Buy |
111,121
+4,006
| +4% | +$364K | ﹤0.01% | 1476 |
|
|
2022
Q4 | $4.07M | Sell |
107,115
-3,318
| -3% | -$126K | ﹤0.01% | 2028 |
|
|
2022
Q3 | $2.78M | Sell |
110,433
-3,213
| -3% | -$80.7K | ﹤0.01% | 2222 |
|
|
2022
Q2 | $3.45M | Buy |
113,646
+8,114
| +8% | +$247K | ﹤0.01% | 2162 |
|
|
2022
Q1 | $3.99M | Buy |
105,532
+8,117
| +8% | +$307K | ﹤0.01% | 2170 |
|
|
2021
Q4 | $2.57M | Sell |
97,415
-7,421
| -7% | -$196K | ﹤0.01% | 2447 |
|
|
2021
Q3 | $10.5M | Sell |
104,836
-61,631
| -37% | -$6.2M | ﹤0.01% | 1741 |
|
|
2021
Q2 | $23.6M | Buy |
166,467
+37,961
| +30% | +$5.37M | 0.01% | 1238 |
|
|
2021
Q1 | $12.8M | Buy |
128,506
+2,001
| +2% | +$200K | ﹤0.01% | 1638 |
|
|
2020
Q4 | $15.6M | Buy |
126,505
+25,285
| +25% | +$3.13M | 0.01% | 1407 |
|
|
2020
Q3 | $9.86M | Sell |
101,220
-9,760
| -9% | -$951K | ﹤0.01% | 1534 |
|
|
2020
Q2 | $17.3M | Sell |
110,980
-77,895
| -41% | -$12.2M | 0.01% | 1140 |
|
|
2020
Q1 | $27.3M | Buy |
188,875
+24,949
| +15% | +$3.6M | 0.01% | 736 |
|
|
2019
Q4 | $33.5M | Sell |
163,926
-10,239
| -6% | -$2.09M | 0.01% | 878 |
|
|
2019
Q3 | $14M | Buy |
174,165
+38,853
| +29% | +$3.12M | 0.01% | 1352 |
|
|
2019
Q2 | $12.8M | Buy |
135,312
+130,494
| +2,708% | +$12.3M | 0.01% | 1449 |
|
|
2019
Q1 | $412K | Buy |
+4,818
| New | +$412K | ﹤0.01% | 865 |
|